CA2787048C - A cut-point in pten protein expression that accurately identifies tumors and is predictive of drug response to a pan-erbb inhibitor - Google Patents

A cut-point in pten protein expression that accurately identifies tumors and is predictive of drug response to a pan-erbb inhibitor Download PDF

Info

Publication number
CA2787048C
CA2787048C CA2787048A CA2787048A CA2787048C CA 2787048 C CA2787048 C CA 2787048C CA 2787048 A CA2787048 A CA 2787048A CA 2787048 A CA2787048 A CA 2787048A CA 2787048 C CA2787048 C CA 2787048C
Authority
CA
Canada
Prior art keywords
pten
protein expression
cell
pten protein
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2787048A
Other languages
English (en)
French (fr)
Other versions
CA2787048A1 (en
Inventor
Christina Marie Coughlin
Anna Berkenblit
Jay Marshall Feingold
Daniel Stephen Johnston
Andrew Louis Strahs
Charles Michael Zacharchuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CA2787048A1 publication Critical patent/CA2787048A1/en
Application granted granted Critical
Publication of CA2787048C publication Critical patent/CA2787048C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2787048A 2010-01-13 2011-01-04 A cut-point in pten protein expression that accurately identifies tumors and is predictive of drug response to a pan-erbb inhibitor Active CA2787048C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29461510P 2010-01-13 2010-01-13
US61/294,615 2010-01-13
PCT/US2011/020080 WO2011087926A1 (en) 2010-01-13 2011-01-04 A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR

Publications (2)

Publication Number Publication Date
CA2787048A1 CA2787048A1 (en) 2011-07-21
CA2787048C true CA2787048C (en) 2021-06-22

Family

ID=43569472

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2787048A Active CA2787048C (en) 2010-01-13 2011-01-04 A cut-point in pten protein expression that accurately identifies tumors and is predictive of drug response to a pan-erbb inhibitor

Country Status (6)

Country Link
US (1) US8338456B2 (cg-RX-API-DMAC10.html)
EP (1) EP2524231B1 (cg-RX-API-DMAC10.html)
JP (2) JP6126382B2 (cg-RX-API-DMAC10.html)
CA (1) CA2787048C (cg-RX-API-DMAC10.html)
ES (1) ES2638821T3 (cg-RX-API-DMAC10.html)
WO (1) WO2011087926A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (en) 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
EP2498751B1 (en) 2009-11-09 2019-04-03 Wyeth LLC Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
CN104010494B (zh) * 2011-07-28 2017-07-04 霍夫曼-拉罗奇有限公司 Pik3ca h1047r敲入非人动物乳腺癌模型
CA2883356A1 (en) * 2012-08-30 2014-03-06 Turun Yliopisto Method of selecting individualized brain cancer therapy
US20200157563A1 (en) * 2017-07-18 2020-05-21 The Broad Institute, Inc. Methods of producing human cancer cell models and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003291736A1 (en) * 2002-11-05 2004-06-03 Cell Signaling Technology, Inc. Methods and materials for examining pathways associated with glioblastoma progression
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
EP1756137A4 (en) 2003-11-05 2007-10-31 Univ Texas DIAGNOSTIC AND THERAPEUTIC PROCEDURES AND COMPOSITIONS CONCERNING PTEN AND BREAST CANCER
WO2006044748A2 (en) * 2004-10-15 2006-04-27 Monogram Biosciences, Inc. RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
WO2006116016A2 (en) * 2005-04-21 2006-11-02 The Regents Of The University Of California Molecular determinants of egfr kinase inhibitor response in glioblastoma
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8700335B2 (en) * 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US8022216B2 (en) * 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2553390T3 (es) * 2008-02-25 2015-12-09 Nestec S.A. Método para la detección de receptores truncados intracelulares
BRPI0911451A2 (pt) * 2008-05-25 2019-09-24 Wyeth Llc biomarcadores para eficácia medicamentosa de egfr/her/erb
EP3075864A1 (en) * 2008-10-14 2016-10-05 Caris MPI, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type

Also Published As

Publication number Publication date
ES2638821T3 (es) 2017-10-24
JP2013517476A (ja) 2013-05-16
CA2787048A1 (en) 2011-07-21
EP2524231B1 (en) 2017-06-28
US8338456B2 (en) 2012-12-25
JP6126382B2 (ja) 2017-05-10
JP2016053579A (ja) 2016-04-14
WO2011087926A1 (en) 2011-07-21
US20120010240A1 (en) 2012-01-12
EP2524231A1 (en) 2012-11-21

Similar Documents

Publication Publication Date Title
US8338456B2 (en) Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor
Zhu et al. UBE2T promotes autophagy via the p53/AMPK/mTOR signaling pathway in lung adenocarcinoma
Paccez et al. Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl
Zhou et al. TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability
Zhou et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers
Mo et al. S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer
Micke et al. C‐erbB‐2 expression in small‐cell lung cancer is associated with poor prognosis
Hussein et al. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer
Banno et al. Biomarkers in endometrial cancer: Possible clinical applications
El-Guindy et al. Oct4 expression in gastric carcinoma: association with tumor proliferation, angiogenesis and survival
Meric-Bernstam et al. Influence of biospecimen variables on proteomic biomarkers in breast cancer
Xu et al. SGK3 is associated with estrogen receptor expression in breast cancer
Chumsri et al. High p95HER2/HER2 ratio associated with poor outcome in trastuzumab-treated HER2-positive metastatic breast cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)
Martinho et al. HER family receptors are important theranostic biomarkers for cervical cancer: blocking glucose metabolism enhances the therapeutic effect of HER inhibitors
Wu et al. AXL–GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases
Wang et al. MACC1 overexpression predicts a poor prognosis for non-small cell lung cancer
Yang et al. Histone acetyltransferase CSRP2BP promotes the epithelial–mesenchymal transition and metastasis of cervical cancer cells by activating N-cadherin
DeCensi et al. Lapatinib activity in premalignant lesions and HER-2–positive cancer of the breast in a randomized, placebo-controlled presurgical trial
Wang et al. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers
Hisamatsu et al. Effect of EGFR and p-AKT overexpression on chromosomal instability in gastric cancer
Rampioni Vinciguerra et al. p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer
Geng et al. SHP-1 acts as a tumor suppressor by interacting with EGFR and predicts the prognosis of human breast cancer
Tian et al. The depletion of PinX1 involved in the tumorigenesis of non-small cell lung cancer promotes cell proliferation via p15/cyclin D1 pathway
Yoshida et al. Integration of NRP1, RGS5, and FOXM1 expression, and tumour necrosis, as a postoperative prognostic classifier based on molecular subtypes of clear cell renal cell carcinoma
Chen et al. TRIP13-induced NUSAP1 upregulation promotes CcRCC progression through EMT and PI3K/AKT/mTOR pathway

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151127

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251202